Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab
| Autor: | Keiko Segawa, Hideki Nakamura, Tomohiro Koga, Kunihiro Ichinose, Atsushi Kawakami, Takahiro Maeda, Shin-ya Kawashiri, Masataka Umeda, Kazusato Hara, Yushiro Endo, Midori Akagi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Apraxias Hearing Loss Sensorineural Giant Cell Arteritis Antibodies Monoclonal Humanized chemistry.chemical_compound tocilizumab Tocilizumab Internal Medicine medicine otorhinolaryngologic diseases Cogan Syndrome Humans Interleukin 6 Keratitis S syndrome biology Cogan’s syndrome business.industry interleukin-6 Headache Interleukin General Medicine Middle Aged medicine.disease Dermatology Giant cell arteritis chemistry biology.protein Temporal artery Sensorineural hearing loss business Scleritis |
| Zdroj: | Internal medicine (Tokyo, Japan). 61(8) |
| ISSN: | 1349-7235 |
| Popis: | A 49-year-old Japanese man with a 2-month history of a fever, headache, and bilateral conjunctival hyperemia was admitted. His condition fulfilled the giant cell arteritis classification criteria (new headache, temporal artery tenderness, elevated ESR) and atypical Cogan’s syndrome (CS) with scleritis and sensorineural hearing loss (SNHL). The interleukin (IL)-6 serum level was extremely high. Two weeks after his insufficient response of SNHL and scleritis to oral prednisolone, we administered tocilizumab (TCZ); rapid improvements in scleritis and SNHL occurred. Early IL-6 target therapy can help prevent irreversible CS-induced sensory organ damage. Internal medicine, 61(8), pp1265-1270; 2022 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|